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ABSTRACT
Objectives: In 2013 malignant endometrial cancers have amounted to 7.3% of all cancers diagnosed among women in the 
report by the Polish National Cancer Registry Raw prevalence rate amounted to 28.7, whereas standardised prevalence rate 
15.6 per 100 000 population. Among the causes of death, these cancers amounted to 3% and were ranked ninth on the list 
of the most common causes of oncologic mortality of women. In the year 2013 a total of 1243 women died of malignant 
endometrial cancers. A stable increase of malignant endometrial cancer incidence has been observed for 2 decades. Despite 
that fact, the increase of the mortality incidence is at a much lower level, which demonstrates the much higher effectiveness 
of the treatment of such cancers. The recording rate of the malignant endometrial cancer mortality amounts to 95%, so the 
presented absolute numbers are reliable. Examining the clinical stages of malignant endometrial cancers, we can establish 
that approx. 85% of them are diagnosed at stage I or II according to the FIGO classification. Patients with advanced stages of 
cancer represent less than 15%.
Material and methods: retrospective analysis of endometrial body cancer prevalence data for the entire population of 
Poland, assessment of malignant endometrial cancer prevalence in the years 2008–2015 and overall survival probability 
in the population of patients undergoing adjuvant chemotherapy.
Results: The number of patients with a diagnosed malignant endometrial cancer within the studied period in Poland remains 
on a stable level (2008 — 30.6 thousand patients, 2015 — 40.2 thousand patients). Among all listed patients with the indica-
tion of C54 each year approx. 20% enters hospital treatment. System therapy with chemotherapy drugs was used in approx. 
1–2% of patients treated in hospitals. The average age of the patients was 64.9 years, and the median age 65 years. The num-
ber of observations was 2085, including 1088 censored observations. The average survival for the sample under study was 
30.67 month (SD = ± 0.6); median survival time was 23.93 month. The number of censored observations was 1088 (52.16%). 
Probable survival of 1 year is achieved by 67.57% of patients, 2 years by 49.73%, 3 years by 40.68%, above 5 years 30.77%.
Conclusions: The incidence of endometrial cancer in Poland in the years 2008–2015 continues to grow at 5% upward trend (in 
Europe 3.4–5.9). In Poland in 2012, crude incidence rate for cancer of the uterus was 29.8 and did not differ significantly from the 
results in countries such as Finland, Slovakia, Sweden, Belgium and Bulgaria. The overall survival after adjuvant chemotherapy for 
patients with malignant endometrial cancer in Poland shows considerable differences depending on the region of the country.
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INTRODUCTION
In 2013 malignant endometrial cancers have amounted 
to 7.3% of all cancers diagnosed among women in the report 
by the Polish National Cancer Registry  Raw prevalence rate 
amounted to 28.7, whereas standardised prevalence rate 
15.6 per 100 000 population [1]. Among the causes of death, 
these cancers amounted to 3% and were ranked ninth on 
the list of the most common causes of oncologic mortality 
of women. In the year 2013 a total of 1243 women died of 
malignant endometrial cancers. 
A stable increase of malignant endometrial cancer inci-
dence has been observed for 2 decades [2]. Despite that fact, 
the increase of the mortality incidence is at a much lower 
level, which demonstrates the much higher effectiveness 
of the treatment of such cancers. The recording rate of the 
malignant endometrial cancer mortality amounts to 95%, 
so the presented absolute numbers are reliable. Examining 
the clinical stages of malignant endometrial cancers, we 
can establish that approx. 85% of them are diagnosed at 
stage I or II according to the FIGO classification. Patients with 
advanced stages of cancer represent less than 15% [3]. The 
results of endometrial cancer treatment in Poland can thus 
be considered satisfying, which distinguishes them from 
other cancers of female reproductive system. Only the ad-
vanced stages of endometrial cancer and type II, which also 
includes carcinosarcoma type tumours have a decidedly 
worse prognosis. In these cases adjuvant therapy is used, 
mainly with the use of cytostatic drugs.
The goal of the study: retrospective analysis of endome-
trial body cancer prevalence data for the entire population 
of Poland, assessment of malignant endometrial cancer 
prevalence in the years 2008–2015 and overall survival prob-
ability in the population of patients undergoing adjuvant 
chemotherapy.
MATERIAL AND METHODS
The reporting databases of the National Health Fund 
(NFZ, the public payer in Poland which finances health 
services in accordance with the legal regulations in force) 
were used to download all patient data from the years 
2008–2015 for analysis, for patients with indication of 
C54%1 – malignant endometrial cancer. Pursuant to the 
patient’s ID (PESEL number) a retrospective analysis of an-
nual and five-year prevalence indicators was conducted 
(for the period of 2010–2015, per 100 000 inhabitants of 
a given province). Subsequently, data concerning solely 
hospital treatments and malignant endometrial cancer pa-
tients undergoing systemic chemotherapy were selected 
from the aforementioned database. Based on the date 
1 The „%” mark replaces any number
of drug administration the overall survival indicator was 
calculated, using the Kaplan-Meier estimator and survival 
tables. The analysis included the patients who underwent 
a systemic therapy with chemotherapy drugs in the years 
of 2011–2015 (5 years). The survival period was calculated 
from the day of first drug administration, and the observa-
tion cutoff date was set on 31 December 2015. The SAS EG 
5.1 software was used for calculations. The demographic 
data was collected from the Central Statistical Office (GUS) 
website. 
RESULTS
The number of patients with a diagnosed malignant 
endometrial cancer within the studied period in Poland 
remains on a stable level (2008, 30.6 thousand patients, 
2015 40.2 thousand patients), with a small increasing trend 
of 5% (SD = ± 1.26 thousand) By provinces, the highest aver-
age annual number of patients was observed in the: Śląskie 
province (5.7 thousand patients) and Mazowieckie province 
(4.4 thousand patients), the smallest number of indicated 
patients was present in Lubuskie province (698 patients). 
Among all listed patients with the indication of C54 each 
year approx. 20% enters hospital treatment. The highest 
average annual number of undergoing hospital treatment 
(SD = ± 0.27 thousand) was observed in the Mazowiec- 
kie province (approx. 1.1 thousand) and Śląskie province 
(approx. 0.9 thousand), the lowest in Lubuskie province 
(0.16 thousand). System therapy with chemotherapy drugs 
was used in approx. 1–2% of patients treated in hospi-
tals. The average age of the patients was 64.9 years, and 
the median age 65 years.   
The annual prevalence indicator per 100 000 inhabitants 
is presented on the map below (Fig. 1).
The prevalence indicator of malignant endometrial 
cancer is highest in the Śląskie, Świętokrzyskie and Ku-
jawsko-Pomorskie provinces, amounting to, respectively, 
123.32, 117.66 and 110.10 persons per 100  000 province 
inhabitants. The lowest values of the indicator are present 
in the Lubuskie (63.38), Małopolskie (72.54) and Łódzkie 
(78.53) provinces.
The periodical prevalence indicator for the 5 year period 
under analysis is presented on Figure 2.
The highest periodic prevalence indicator of malignant 
endometrial cancer occurred in the Świętokrzyskie, Śląskie, 
and Mazowieckie provinces, amounting to, respectively, 
348.34, 338.10 and 304.31 persons per 100 000 province 
inhabitants. The lowest values of the indicator are present 
in the Podkarpackie (236.51), Małopolskie (256.94) and Lu-
buskie (260.39) provinces.
To calculate the overall survivability (OS) rate, patients 
undergoing chemotherapy (standard and non-standard) 
in the period of 2011–2015 were selected, the sample size 
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amounted to 2085 persons, (Fig. 3). The median observation 
time was 28.66 months, standard deviation 0.60 month with 
a 95% confidence level.
The number of observations was 2085, including 
1088 censored observations. The average survival for the 
sample under study was 30.67 month (SD = ± 0.6); me-
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Figure 1. Average annual prevalence indicator for patients with C54% in Poland over the analysed period
Figure 2. Periodic prevalence indicator for the 5 year period of observation 
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dian survival time was 23.93 month. The number of censored 
observations was 1088 (52.16%). Probable survival of 1 year 
is achieved by 67.57% of patients, 2 years by 49.73%, 3 years 
by 40.68%, above 5 years 30.77%. 
DISCUSSION
Malignant endometrial cancers become an increasingly 
important public health problem. An increasing trend is be-
ing observed both in Poland and in other areas of Europe. 
In accordance with data published by GLOBCAN a total of 
5912 cases of malignant endometrial cancers were recorded 
in Poland in 2012. Raw prevalence indicator amounted to 
29.8 in our country. Similar indicators were found in Slova-
kia: 32.9, Finland: 31.3, Sweden: 30, Bulgaria 33.5, Belgium 
27.6 [4]. Raw prevalence indicator in all developed countries 
exceeds 26. This high number of cancers is mainly a result of 
the following risk factors: obesity, hypertension, diabetes, 
hormonal disorders or tamoxifene treatment and Lynch 
syndrome [5–7]. The prevalence of these ailments, common 
in modern societies, is increasing. The conducted retro-
spective analysis of the Polish payer’s data has confirmed 
an increasing trend of 5% per annum, which places Poland 
in the middle of the ranking for European countries. The 
growth rate in the remaining European Union countries 
varies within a range of 3.4–5.9% [4].
A positive phenomenon demonstrated by the analy-
sis is a low increase of malignant uterine cancer mortal-
ity. The absolute number of deceased is increasing, but 
the standardised mortality indicators decrease, which in 
1980 amounted to 2.8 whereas in 2013 to 2.4. It may be 
estimated that the main factor behind the decrease in Po-
land is the high percentage of diagnoses of the illness at 
the early clinical stages. Despite an adverse age structure 
of the malignant endometrial cancer patients significant 
disproportion in the percentage of 5-year survival between 
the early and advanced clinical cancer stages may be ob-
served. According to the data published so far [8–10, 12] 
these values for early stages of advancement amount to 
87–95%, whereas for advanced cases 19.8–48.8%. Data on 
patients in advanced stages of cancer or undergoing relapse 
of cancer after chemotherapy received by the authors in 
the analysis indicate that the percentage of patients living 
5 years or more amount to 30.77%. The survival probabil-
ity for 50% of this population amounts to an average of 
30 months. Similar indicator values can be observed in other 
Central Europe countries [11]. German states achieve some-
what better results, with indicator higher by 4–6% [10]. The 
reasons for differences between German states and other 
European countries should be probably attributed to a dif-
ferent, perhaps better organisation of oncologic care and 
higher number of active clinical trials, to which patients in 
advanced clinical stages of the cancer are enrolled.
The results of the analysis based on regional data indicate 
that the number of patients in individual provinces is varied 
(Tab. 1). The differences of a 15-fold change year to year may 
indicate that there are no established uniform therapeutic 
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Figure 3. Survival probability for endometrial cancer patients using 
Kaplan-Meier method 
Table 1. Number of patients with a diagnosis of C54% for all types of medical services, in hospital treatment and with used chemotherapy
The total number of patients diagnosed with C54%  reported for all levels of care
2008 2009 2010 2011 2012 2013 2014 2015
DOLNOŚLĄSKIE 2 052 2 393 2 314 2 381 2 546 2 657 2 849 2 897
KUJAWSKO-POMORSKIE 2 012 2 197 2 220 2 250 2 351 2 413 2 453 2 520
LUBELSKIE 1 864 1 926 1 897 2 049 2 143 2 261 2 412 2 571
LUBUSKIE 604 686 674 691 732 725 752 720
ŁÓDZKIE 1 660 1 926 1 876 1 906 1 918 2 084 2 144 2 246
MAŁOPOLSKIE 2 284 2 429 2 351 2 399 2 375 2 471 2 567 2 646
MAZOWIECKIE 3 793 3 810 3 945 4 249 4 506 4 587 4 919 5 114
OPOLSKIE 934 956 938 988 1 034 1 107 1 163 1 189
PODKARPACKIE 1 446 1 562 1 378 1 472 1 607 1 919 1 881 2 082
PODLASKIE 950 1 076 1 380 1 359 1 151 1 186 1 155 1 154
→
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Table 1 (cont.). Number of patients with a diagnosis of C54% for all types of medical services, in hospital treatment and with used chemotherapy
The number of patients diagnosed with C54%  reported for all levels of care
2008 2009 2010 2011 2012 2013 2014 2015
POMORSKIE 1 797 1 885 1 945 2 016 2 114 2 301 2 263 2 385
ŚLĄSKIE 5 142 5 643 5 345 5 416 5 639 5 928 6 110 6 459
ŚWIĘTOKRZYSKIE 1 244 1 350 1 434 1 482 1 524 1 549 1 622 1 706
WARMIŃSKO-MAZURSKIE 1 224 1 277 1 275 1 332 1 408 1 527 1 601 1 615
WIELKOPOLSKIE 2 486 2 558 2 582 2 730 2 840 2 968 3 053 3 185
ZACHODNIOPOMORSKIE 1 179 1 289 1 308 1 373 1 401 1 512 1 670 1 712
The number of patients with C54% under hospital care
2008 2009 2010 2011 2012 2013 2014 2015
DOLNOŚLĄSKIE 544 422 389 424 443 455 515 571
KUJAWSKO-POMORSKIE 459 454 460 449 487 468 492 513
LUBELSKIE 381 353 334 374 386 438 472 448
LUBUSKIE 156 145 131 158 169 162 156 186
ŁÓDZKIE 525 529 495 485 521 551 567 583
MAŁOPOLSKIE 598 637 621 643 597 672 678 734
MAZOWIECKIE 956 1 077 1 069 1 022 1 034 1 128 1 213 1 253
OPOLSKIE 184 207 177 162 203 229 215 223
PODKARPACKIE 365 361 355 420 393 378 425 432
PODLASKIE 257 236 250 230 211 228 219 268
POMORSKIE 366 375 347 326 313 404 352 408
ŚLĄSKIE 949 959 924 885 847 891 914 1 080
ŚWIĘTOKRZYSKIE 250 268 288 264 193 209 201 356
WARMIŃSKO-MAZURSKIE 214 201 169 145 172 208 214 203
WIELKOPOLSKIE 601 613 668 740 718 748 769 862
ZACHODNIOPOMORSKIE 288 204 223 262 268 284 308 332
The number of patients with C54% who have undergone chemotherapy
2008 2009 2010 2011 2012 2013 2014 2015
DOLNOŚLĄSKIE 76 11 12 2 9 17 13 35
KUJAWSKO-POMORSKIE 34 40 45 47 73 83 66 54
LUBELSKIE 37 6 9 8 12 8 4 8
LUBUSKIE 15 4 13 4 7 16 14 3
ŁÓDZKIE 47 96 50 20 22 30 11 9
MAŁOPOLSKIE 79 96 119 17 5 7 16 25
MAZOWIECKIE 108 118 56 16 101 152 161 179
OPOLSKIE 29 30 15 1
PODKARPACKIE 15 4 4 8 21 6 6 5
PODLASKIE 27 36 50 46 48 13 15 37
POMORSKIE 22 20 13 22 1 7 11 11
ŚLĄSKIE 71 50 48 24 20 29 52 58
ŚWIĘTOKRZYSKIE 23 25 23 26 10 3 2
WARMIŃSKO-MAZURSKIE 7 1 3 1 6 8 16
WIELKOPOLSKIE 75 85 113 124 119 147 155 167
ZACHODNIOPOMORSKIE 11 21 28 20 8 5 7 21
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paths (differences in the therapy between provinces) or that 
there is a significant migration of patients with advanced 
cancers between provinces. However, when analysing the 
number of procedures reported within the C54 group the val-
ues are proportional, which indicates that the first conclusion 
is correct. The comparison of a one-year and five-year preva-
lence indicator in individual provinces indicates that the high-
est values may be observed in the Śląskie and Świętokrzyskie 
province, whereas the Łódzkie and Mazowieckie provinces 
have a low single year prevalence indicator, and a much 
higher indicator in the five year period. 
The analysis of data collected by the public payer in 
Poland indicates very significant interdependencies from 
the point of view of epidemiological knowledge concerning 
malignant endometrial cancer. By correlating the obtained 
results with data obtained from the Polish National Cancer 
Registry one may conclude that the treatment results for 
malignant endometrial cancer patients are within the range 
of results obtained in other European Union countries. How-
ever, the subsequent analyses should analyse the reasons 
and eliminate the variability of the calculated indicators in 
annual periods (year to year) in the system treatment of the 
patients with the aforementioned cancers. 
CONCLUSIONS
1. The incidence of endometrial cancer in Poland in the 
years 2008–2015 continues to grow at 5% upward trend 
(in Europe 3.4–5.9).
2. In Poland in 2012, crude incidence rate for cancer of the 
uterus was 29.8 and did not differ significantly from the 
results in countries such as Finland, Slovakia, Sweden, 
Belgium and Bulgaria.
3. The overall survival after adjuvant chemotherapy for 
patients with malignant endometrial cancer in Poland 
shows considerable differences depending on the re-
gion of the country.
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